The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Open accessAbstract
Background: This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. Methods: A committee was composed of multidisciplinary experts in ILD, methodologists, and patient representatives. 1) Update of IPF: Radiological and histopathological criteria for IPF were updated by consensus. Questions about transbronchial lung cryobiopsy, genomic classifier testing, antacid medication, and antireflux surgery were informed by systematic reviews and answered with evidence-based recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. 2) Progressive pulmonary fibrosis (PPF): PPF was defined, and then radiological and physiological criteria for PPF were determined by consensus. Questions about pirfenidone and nintedanib were informed by systematic reviews and answered with evidence-based recommendations using the GRADE approach. Results: 1) Update of IPF: A conditional recommendation was made to regard transbronchial lung cryobiopsy as an acceptable alternative to surgical lung biopsy in centers with appropriate expertise. No recommendation was made for or against genomic classifier testing. Conditional recommendations were made against antacid medication and antireflux surgery for the treatment of IPF. 2) PPF: PPF was defined as at least two of three criteria (worsening symptoms, radiological progression, and physiological progression) occurring within the past year with no alternative explanation in a patient with an ILD other than IPF. A conditional recommendation was made for nintedanib, and additional research into pirfenidone was recommended. Conclusions: The conditional recommendations in this guideline are intended to provide the basis for rational, informed decisions by clinicians.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“there remain only two pharmacologic treatments recommended for use – nintedanib and pirfenidone [9–11]. Additionally, both of these medications are only conditionally recommended based on moderate confidence in effect estimates”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, two agents, pirfenidone and nintedanib are approved for this disease and both have been shown to reduce the rate of decline in lung function in patients with IPF.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Idiopathic pulmonary fi brosis (IPF) and progressive pulmonary fi brosis (PPF) are fi brotic interstitial lung diseases (ILDs) that are associated with irreversible loss of lung function and poor prognosis (1).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationTravis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
Self-citationDiagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Self-citationClinical Practice Guidelines We Can Trust
Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Board on Health Care Services, & Institute of Medicine (2011) · National Academies Press eBooks · doi:10.17226/13058 · Cited by 3,081
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
Self-citationRaghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citationAcute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Self-citationReyfman, P. A., Walter, J. M., Joshi, N., Anekalla, K. R., McQuattie-Pimentel, A. C., Chiu, S., Fernandez, R., Akbarpour, M., Chen, C.-I., Ren, Z., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201712-2410oc · Cited by 1,203
Habermann, A. C., Gutierrez, A. J., Bui, L. T., Yahn, S. L., Winters, N. I., Calvi, C. L., Peter, L., Chung, M.-I., Taylor, C. J., Jetter, C., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba1972 · Cited by 1,129
Raghu, G., Remy-Jardin, M., Ryerson, C. J., Myers, J. L., Kreuter, M., Vasakova, M., Bargagli, E., Chung, J. H., Collins, B. F., Bendstrup, E., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202005-2032st · Cited by 1,047
Self-citation
Research works printed but not linked: 10
- Kheir F, Ann Am Thorac Soc
- Hagmeyer L, 2016, Sarcoidosis Vasculitis Diffuse Lung Dis, 33, 2
- Linhas R, 2017, Rev Port Pneumol (2006), 23, 331
- Kheir F, Ann Am Thorac Soc
- Khor YHBB, Ann Am Thorac Soc
- Liu B, 2017, Int J Clin Exp Med, 10, 5805
- Umeda T, 2018, Am J Respir Crit Care Med, 159, A4256
- Kreuter M, 2020, Eur Respir J, 56, 3713
- Ghazipura MHT, Ann Am Thorac Soc
- Ghazipura MHM, Ann Am Thorac Soc
Cited by
Idiopathic pulmonary fibrosis: state of the art for 2023
Podolanczuk, A. J., Thomson, C. C., Remy-Jardin, M., Richeldi, L., Martinez, F. J., Kolb, M., & Raghu, G. (2023) · European Respiratory Journal · doi:10.1183/13993003.00957-2022 · Cited by 359
Self-citationNerandomilast in Patients with Idiopathic Pulmonary Fibrosis.
Richeldi, L., Azuma, A., Cottin, V., Kreuter, M., Maher, T. M., Martinez, F. J., Oldham, J. M., Valenzuela, C., Clerisme-Beaty, E., Gordat, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2414108 · Cited by 297
Self-citationXu, Z., Ren, F., Wang, P., Cao, J., Tan, C., Ma, D., Zhao, L., Dai, J., Ding, Y., Fang, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03743-2 · Cited by 180
“Eligible patients were 40 years of age or older with an IPF diagnosis as defined by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Latin American Thoracic Association guidelines 62 .”
Idiopathic pulmonary fibrosis.
Koudstaal, T., & Wijsenbeek, M. S. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104166 · Cited by 105
Self-citationPhosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
Kolb, M., Crestani, B., & Maher, T. M. (2023) · European Respiratory Review · doi:10.1183/16000617.0206-2022 · Cited by 85
Self-citation
Metadata
- Authors
- Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., Molina-Molina, M., Myers, J. L., Nicholson, A. G., Ryerson, C. J., Strek, M. E., Troy, L. K., Wijsenbeek, M., Mammen, M. J., Hossain, T., Bissell, B. D., Herman, D. D., Hon, S. M., Kheir, F., Khor, Y. H., Macrea, M., Antoniou, K. M., Bouros, D., Buendia-Roldan, I., Caro, F., Crestani, B., Ho, L., Morisset, J., Olson, A. L., Podolanczuk, A., Poletti, V., Selman, M., Ewing, T., Jones, S., Knight, S. L., Ghazipura, M., & Wilson, K. C.
- Affiliations
- University of Washington Medical Center (US)
- Corresponding author
- Raghu, Ganesh
- ORCID
- Raghu, Ganesh
- Remy-Jardin, Martine
- Richeldi, Luca
- Thomson, Carey C.
- Inoue, Yoshikazu
- Johkoh, Takeshi
- Kreuter, Michael
- Lynch, David A.
- Maher, Toby M.
- Martinez, Fernando J.
- Molina-Molina, Maria
- Myers, Jeffrey L.
- Nicholson, Andrew G.
- Strek, Mary E.
- Troy, Lauren K.
- Wijsenbeek, Marlies
- Mammen, Manoj J.
- Hossain, Tanzib
- Bissell, Brittany D.
- Hon, Stephanie M.
- Khor, Yet H.
- Macrea, Madalina
- Buendia-Roldan, Ivette
- Caro, Fabian
- Crestani, Bruno
- Ho, Lawrence
- Olson, Amy L.
- Podolanczuk, Anna
- Selman, Moisés
- Knight, Shandra L.
- Ghazipura, Marya
- Wilson, Kevin C.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-05-01
- Volume
- 205
- Issue
- 9
- Pages
- e18-e47
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC9851481
- OpenAlex
- W4225147016
- Cited by
- 2,957
- References
- 180
- Citations by year
- 2026: 720 · 2025: 786 · 2024: 728 · 2023: 559 · 2022: 163
- FWCI
- 361.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Funders
- American Thoracic Society
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, interstitial lung disease, transbronchial cryobiopsy, antireflux surgery, pirfenidone, nintedanib, radiographic progression, histopathological criteria
- MeSH terms
- Antacids, Biopsy, Humans, Lung, United States, Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. https://app.cochat.ai/papers/10.1164/rccm.202202-0399st
- The paper
- Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., Molina-Molina, M., Myers, J. L., Nicholson, A. G., Ryerson, C. J., Strek, M. E., Troy, L. K., Wijsenbeek, M., Mammen, M. J., Hossain, T., . . . Wilson, K. C. (2022). Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.202202-0399st
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.